シャドーイング練習: 2025 Pathology Review: Practical Updates in Breast, Gastrointestinal and Genitourinary Pathology - YouTubeで英語スピーキングを学ぶ
C1
I have the opportunity to talk about renal cell tumors,
111 文
文が短すぎたり長すぎる場合は、Editをタップして調整してください。
1
I have the opportunity to talk about renal cell tumors,
2
which is one of my favorite topics.
3
Feel free to reach out afterwards if you have any questions or anything like that.
4
And of course, live, I'll be happy to answer any questions here. So first,
5
let's just start off with sort of an introduction about renal
6
cell tumors kind of go through in a pattern-based approach by some of the more common patterns,
7
clear cell, papillary, and eosinophilic,
8
and then talk about some other tumors.
9
What's important about renal tumor pathology?
10
Well, I think nowadays we might be asked to do more with less.
11
That is, we might be asked to diagnose renal mass biopsies more regularly or perhaps biopsies from metastatic sites of renal cancer.
12
And it may be tricky with just a very small visualization of the tumor.
13
is a trend toward less aggressive management of renal tumors.
14
So if you have a very small renal mass,
15
there may be consideration for surveillance.
16
And so the diagnosis that we make in a biopsy could be relevant for surveillance.
17
And then there's increasing recognition that renal cell cancer is more than one disease.
18
And trying to divide them into clear cell or non-clear cell types may be important for management purposes,
19
especially when you have metastatic renal cancer.
20
Clinicians would like to know ideally if we have a clear cell or non-clear cell tumor.
21
So here's just an example of what might happen based on a renal mass biopsy.
22
So say a renal mass biopsy is performed,
23
this is from a publication in the Journal of Urology several years ago.
24
If the histology is benign,
25
like for example angiomyelipoma, then nothing further needs to be done.
26
But if you have a very low-risk tumor like a chromophobe renal cell carcinoma or a low-grade papillary renal cell carcinoma,
27
this algorithm suggests that active surveillance would be reasonable.
28
As you have kind of intermediate risk tumors,
29
like a clear cell of grade 1 to 2 or a higher grade papillary tumor,
30
the algorithm kind of figures that depending on tumor size,
31
if you have a very small size,
32
that may be amenable to active surveillance.
33
But as the size is larger,
34
that may be a candidate for surgery.
35
And then very high-risk tumors are kind of automatically a candidate for surgery,
36
such as tumors that are grade three or urothelial carcinomas or comatoid or unclassified renal cell carcinomas.
37
So just an example of what might happen based on renal mass biopsy.
38
The way I kind of approach it is that if a renal mass biopsy is being done,
39
it probably means that the clinicians are thinking of doing something different other than the routine resection of the renal mass.
40
And so I should think about sort of the risk of the tumor
41
and try to do my best to classify it into a specific box,
42
whether it's a high or low risk tumor.
43
So if you have a patient that perhaps is elderly with multiple comorbidities,
44
that may be an indication for surveillance.
45
So a biopsy might be done considering that surveillance would be undertaken for a patient who has perhaps not an extreme...
46
We're going to do some sneaky cancers in gastric biopsies.
47
Everyone's favorite topic.
48
Puts hair on your chest.
49
I have no conflicts to report and so today in this discussion we're going to focus on like two broad categories.
50
Benign mimics of gastric cancer in biopsy samples.
51
Talking about macrophages and epithelial mimics.
52
And then carcinomas that simulate benign conditions both diffuse type and tubular type carcinomas.
53
So let's start off with benign mimics of carcinoma.
54
The major situation in which you're going to come up against benign repair type changes
55
that simulate neoplasia are in the context of chemical gastropathy with ulcers.
56
What happens is you'll, and there are a lot of different scenarios,
57
the epithelial cell atypia related to repair,
58
gastric xanthomas or macrophage responses to ruptured epithelial cells,
59
sloughed mucus neck cells that simulate signet ring cell carcinoma,
60
tissue processing artifacts, and mucosal ischemia.
61
So you'll remember from a few days ago,
62
chemical gastropathy, we see a diffuse alteration in the epithelial cell morphology
63
and architecture without much inflammation to explain those So the pits are elongated
64
and they're lined by cells that are cytoplasmically depleted with a nuclear enlargement and scattered mitotic activity.
65
Most of the time what you can appreciate is
66
that there's maturation of this epithelial cell atypia as you move to the surface of the mucosa.
67
You can get into trouble when there are erosions in areas of extreme repair because that induces even more cytologic abnormalities,
68
as you can see here.
69
A few clues that you're dealing with a benign process.
70
You see superficial fragments that do show maturation,
71
and the overall proliferation respects the boundaries within the mucosa,
72
so you'll see that there is a lobular architecture overall with preserved bundles of smooth muscle cells and vessels permeating the mucosa.
73
Higher power, you can see some of that cytologic atypia over here.
74
In general, I would say don't make a diagnosis of low-grade dysplasia
75
and be very careful about a carcinoma diagnosis in the setting of chemical gastropathy with an erosion.
76
My colleague Liz Montgomery some time ago published a paper talking about repair type atypia in Barrett esophagus
77
and in the gastric mucosa and described what she calls the four lines of maturation in benign epithelium or non-neoplastic epithelium.
78
And I think it's a helpful thing to keep in mind
79
when you're approaching repair-type changes in the stomach and in the distal esophagus.
80
And what she was talking about is when you have In this presentation,
81
I will talk about breast pathology in the area of genomics.
82
Molecular testing has been increasingly used in breast cancer diagnosis and treatment.
83
In this presentation, I will use some case examples to illustrate how we use molecular testing to help us with tumor classification,
84
diagnosis, and treatment.
85
As a surgical pedologist, we don't have to personally do molecular testing,
86
but it's important to know using it as a tool to help us interpreting difficult cases.
87
So for two more classification,
88
we talk about this in our triple negative breast cancer presentation.
89
Certain special histological subtypes of carcinoma,
90
breast carcinomas, have characteristic somatic genomic alterations.
91
In difficult cases, we could use these alterations to help us to confirm the diagnosis.
92
For example, I know cystic carcinoma has maybe NFIB rearrangement or maybe L1 rearrangement, maybe amplification.
93
I don't always do this testing.
94
If histologically is consistent, I'll go ahead and make the diagnosis.
95
But in difficult cases, we can do in situ hybridization,
96
sequencing analysis, or recently We have been using immunoskeministry as a surrogate to detect the genomic alteration.
97
Another tumor is this one,
98
secretory carcinoma, has characteristic ETV6 N-TRAC fusion.
99
Again, we can use FISH or sequencing analysis or immunoskeministry for PANTRAC to confirm the diagnosis if histologically it's not classic,
100
it's not definitive.
101
This is another tumor with unique mutation profile we talk about.
102
Tall cell carcinoma with reverse polarity has unique IDH2 R172 hotspot mutation.
103
This can be detected by sequencing analysis or immunosupportism chemistry using mutation specific immunosupportism chemistry assay.
104
So I don't want to repeat too much.
105
I'll move on to case examples to show how we use molecular testing,
106
helping us in diagnosis in difficult cases.
107
So this case, a patient was a 40-year-old woman with rapidly growing mass in the breast,
108
almost 5 centimeters at presentation.
109
had a core biopsy diagnosis, proceeded with mastectomy.
110
I'll show you some images from her mastectomy specimen.
111
This is the...
アプリをダウンロード
話したすべての文をAIが採点
TRENDING
人気動画
このレッスンについて
このレッスンでは、腎細胞腫瘍の病理学に関する最新の知識を学び、特に生検結果に基づく患者管理の違いについて考察します。クリア細胞、腺腫、好酸球腫瘍などの一般的なパターンを通じて、臨床医が腎腫瘍に対しどのようにアプローチするべきか理解を深めます。また、早期発見と監視の重要性についても触れ、患者の状態に応じた適切な対策について考えます。このレッスンを通して、英語のリスニングとスピーキングスキルを向上させることができます。
重要な語彙とフレーズ
- 腎細胞腫瘍 (renal cell tumors)
- 生検 (biopsy)
- 監視 (surveillance)
- 悪性腫瘍 (malignant tumors)
- 良性 (benign)
- 高リスク/低リスク (high risk/low risk)
- 腫瘍のパターン (tumor patterns)
- 臨床医 (clinician)
練習のコツ
このビデオでは、話し手のトーンが明確で、専門用語が多く使われています。同じ内容を繰り返すことで、リスニング力とスピーキング力を向上させることが可能です。具体的には、shadowingテクニックを用いて、話し手のスピードに合わせて話す練習をしましょう。ビデオを複数回視聴し、初めは言葉を真似することを意識し、次第に内容を理解しながらスローで話すことが大切です。毎回「YouTubeで英語学習」を楽しんで、新しい語彙を習得しながら、自信を持って話せるようになりましょう。特に、shadowspeakやshadow speechを意識して、正しい発音やイントネーションを響かせてみてください。
シャドーイングとは？英語上達に効果的な理由
シャドーイング（Shadowing）は、もともとプロの通訳者養成プログラムで開発された言語学習法で、多言語習得者として知られるDr. Alexander Arguelles によって広く普及されました。方法はシンプルですが非常に効果的：ネイティブスピーカーの英語を聞きながら、1〜2秒の遅延で声に出してすぐに繰り返す——まるで「影（shadow）」のように話者を追いかけます。文法ドリルや受動的なリスニングと異なり、シャドーイングは脳と口の筋肉が同時にリアルタイムで英語を処理・再現することを強制します。研究により、発音精度、抑揚、リズム、連音、リスニング力、そして会話の流暢さが大幅に向上することが確認されています。IELTSスピーキング対策や自然な英語コミュニケーションを目指す方に特におすすめです。